The FY22 Defense Appropriations Act provides funding for the MRP to support innovative, high-impact melanoma research.  The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY22 MRP funding opportunity announcements for the following award mechanisms is posted on the Grants.gov website. 

Applications submitted to the FY22 MRP must address one or more of the following Focus Areas:

• ·        Investigate topics relevant to rare melanomas (e.g., uveal, acral, mucosal melanoma, etc.) that cover the entire research spectrum, from risk factors and initiation to distant macro-metastases, in model organisms and/or patients.
• ·        Identify and understand risk factor determinants for melanoma.
• ·        Develop prediction and surveillance tools for distinguishing patient populations at risk for a second primary diagnosis, recurrence, and/or metastasis.
• ·        Understand how precursor lesions and environmental/endogenous factors influence melanomagenesis, including, but not limited to, the skin microbiome, race, and biological sex as a variable.
• ·        Develop new tools for the detection and diagnosis of melanoma, which includes easily accessible technology (beyond the dermoscope) for primary care physicians and dermatologists.
• ·        Identify how the tumor microenvironment (e.g., stromal, immune, microbiome) impacts tumor initiation, response to therapy, progression, recurrence, and/or dormancy.
• ·        Delineate the molecular pathways that influence metastatic spread, recurrence, and/or dormancy.

The MRP challenges the research community to redefine the concept of prevention and has issued a FY22 MRP Challenge Statement that must be addressed when responding to the FY22 MRP Focus Areas and funding opportunities. For additional information, applicants are encouraged to review the FY21 MRP Landscape and abstracts from previously funded MRP awards.

Funding Opportunities-FY22 Melanoma Research Program, Congressionally Directed Medical Research Programs (CDMRP) (army.mil)

Idea Award – Preproposal due July 8, 2022

Independent investigators with a faculty-level appointment (or equivalent)

• ·       Preproposal is required; application submission is by invitation only.
• ·       Supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research that are beyond an incremental advancement.
• ·       Emphasis on innovation and impact.
• ·       Must address at least one of the FY22 MRP Focus Areas.
• ·       Preliminary data are not required.
• ·       Clinical trials are not allowed.
• ·     The maximum allowable funding for the entire period of performance is $500,000 for direct costs.
• ·     Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·     The maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

  For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca.

The Terry Fox New Investigator Award provides research operating grants to support future leaders as they develop their independent careers in cancer research. The award provides a single research grant of up to $450,000 for three years to investigators within the first five years of a first faculty-level appointment in Canada.

The Terry Fox New Frontiers Program Project Grants is a long‐standing program involving the best cancer researchers in Canada. These programs support Canadian research teams exploring new frontiers in cancer research (i.e., breakthrough and transformative biomedical, clinical and translational research which may form the basis for innovative cancer prevention, diagnosis and/or treatment).

OHTN has launched a new call for the HIV Endgame Program.

The OHTN will offer seven types of grants:

1. Winston Husbands Leadership Award in Strengthening the Response to HIV Among Black Communities: salary support for emerging Black scholars, knowledge users, and service providers who work collaboratively with community stakeholders to understand and address the impact of HIV on African, Caribbean, and Black communities in Ontario
2. Junior Investigator Grant: salary support for emergent leaders in HIV inquiry who are preparing to establish an HIV program of data, evidence-sharing, and impact.
3. Student Leadership Grant: for excellent PhD students who are interested in working closely and collaboratively with the OHTN to drive change, contribute to rapid learning and improvement in our sector, and build HIV innovation capacity in Ontario.
4. Breaking New Ground Grant: project funding for innovative, high-reward projects that will break new ground and build evidence and programs to dramatically improve the prevention, treatment, and care cascade in Ontario. This funding stream supports the piloting, evaluation, or scale up of HIV interventions
5. Implementation Science Grant: project funding for the development of sustainable, effective HIV programs and services. This funding stream will support implementation science initiatives that will contribute to a rapid learning system for HIV.
6. Community Based Project and Participatory Evaluation Grant: support for community-based agencies, their staff, and people living with HIV to undertake projects, needs assessments, quality improvements, and evaluation activities that help develop and modify effective programs, services, and policies or generate data to make the case for additional HIV inquiry relevant to Ontario’s needs.
7. Incubator Grant: project funding to establish high-risk, high-reward initiatives that will test, evaluate, and scale up innovative interventions and effective programs and services. The intervention should be solution-focused, ready for implementation, disruptive to the system, or act as accelerator to close gaps in HIV prevention, treatment, and care, and provide timely and early access to data. Monthly uptake of proposals.

Priorities

Through a strategic planning process and stakeholder consultations, OHTN has identified seven priorities or key learning areas:

1. Effective PrEP scale-up in Ontario
2. Population-focused prevention and health promotion
3. HIV testing
4. Linkage, adherence, and retention in care
5. Clinical care standards and capacity
6. Integration of services
7. Mental health and well-being of people living with and at risk of HIV (including stigma reduction)

Please see grant application guidelines for additional priority areas.

Review Process

A diverse OHTN Review Committee will review and appraise every proposal submitted to the HIV Endgame Program. Review criteria are included in the application guidelines.

Important Deadlines

LOI Application Deadline: July 18, 2022 at 12pm EST

Results of LOI: mid-August 2022

Full Application Deadline: October 17, 2022 at 12pm EST

Information Session: June 28 at 12pm EST. Please RSVP to funding@ohtn.on.ca by June 24 at 5pm.

Please review the application guidelines, as deadlines differ for each grant.

Brain Canada is pleased to be partnering with Alzheimer’s Association (ALZ) to launch the Advancing Research on Care and Outcome Measurement 2.0 (ARCOM-2) funding program, an international and collaborative competition aimed at addressing significant gaps in care and outcome measurement and providing an opportunity to advance research so that care providers can ensure that they are implementing evidence-based practices and achieving desired outcomes.

Areas of interest for this program include, but are not limited to, care preferences, behavioral expressions, quality metrics, and systems of care in the area of Alzheimer’s or other dementia. Through this partnership, Brain Canada will co-fund up to five (5) successful Canadian-led teams who meet peer review recommendations. Each award is limited to USD $250,000 over a period of up to two years.

Evidence clearly shows that increasing equity, diversity and inclusion (EDI) in research environments enhances excellence, innovation and creativity. Brain Canada and ALS Canada are committed to excellence through equity and encourage applicants of diverse backgrounds to apply to our funding opportunities. 

Deadline for receipt of Letters of Intent: July 13, 2022 at 17:00 ET

Deadline for receipt of Full Applications: September 9, 2022 at 17:00 ET

For more information, please review the Request for Application

IDRC requests proposals for a team to conduct an evaluation of Knowledge sharing for a more sustainable and inclusive world: an evaluation of program support models for knowledge translation in IDRC-funded research. 

If high-quality research and innovation are to have an impact on development, the resulting knowledge must be clear, accessible and relevant for users. In collaboration with our grantee research partners and other strategic partners, IDRC is committed to synthesizing and sharing findings and evidence from across our research investments to influence local, regional, and global agendas. Through these efforts, IDRC works to ensure that the research we fund is more visible and useful to targeted stakeholders — and that it enhances the ability of developing countries to tackle their most pressing priorities and contribute solutions to global challenges.

Please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca for more information.

Deadline: June 22, 2022, 13:00 Eastern Daylight Time (EDT)

For FY22, congress transitioned the Neurotoxin Exposure Treatment Parkinson’s (NETP) program to PRP and broadened the research from neurotoxin exposure treatment PD research to all types of PD research.  Applicants with toxic exposure research are directed to the Toxic Exposure Research Program at CDMRP.

The FY22 PRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY22 PRP must address one or more of the following Focus Areas:

• Biological mechanisms and biomarkers of non-motor symptoms that could lead to the development of treatments for PD. Examples of non-motor symptoms of interest:

○       Cognitive dysfunction relevant to PD

○       Psychiatric dysfunction

○       Sleep and circadian rhythms disruptions

○       Autonomic dysfunction

○       Sensory dysfunction

○       Fatigue

• Biological mechanisms and biomarkers of non-pharmacological interventions for non-motor symptoms in PD.

○       Exercise

○       Diet

○       Neuro stimulation therapy

○       Neurosurgical

○        

Funding Opportunities-FY22 PRP, Congressionally Directed Medical Research Programs (CDMRP) (army.mil)

Investigator-Initiated Research Award – Letter of Intent due August 16, 2022

Independent investigators at or above the level of assistant professor (or equivalent)

• ·     Supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s research.  This award mechanism supports the full spectrum of research from basic science through clinical research.
• ·     Must address at least one of the FY22 PRP Focus Areas.
• ·     Preliminary data to support feasibility are encouraged but not required.
• ·     Submission of a Letter of Intent is required prior to full application submission. 
• ·     Clinical trials are allowed.
• ·    The maximum allowable funding for the entire period of performance is $1.2 million (M) for total costs (includes direct and indirect costs)
• ·    The maximum period of performance is 3 years.

Early Investigator Research Award – Letter of Intent due August 16, 2022

Investigator must be a postdoctoral or clinical fellow, instructor, or assistant professor within 10 years of advanced degree or residency training completion (or equivalent).

• ·     Supports research opportunities for investigators in the early stages of their careers and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research.
• ·     Principal Investigators (PIs) must have at least one Mentor, who has experience in Parkinson’s disease (PD) research and mentorship.
• ·     Must address at least one of the FY22 PRP Focus Areas.
• ·     Preliminary data are not required but encouraged.
• ·     Submission of a Letter of Intent is required prior to full application submission. 
• ·     Clinical trials are not allowed.
• ·    The maximum allowable funding for the entire period of performance is $400,000 for total costs (includes direct and indirect costs)
• ·    The maximum period of performance is 2 years

Synergistic Idea Award – Letter of Intent due August 16, 2022

Independent investigators at or above the level of assistant professor (or equivalent)

• ·     Supports new ideas that represent synergistic approaches to PD research involving two to four PIs at the assistant professor (or equivalent) level or above.
• ·     The combined efforts of the PIs should utilize their complementary and synergistic perspectives to address a central problem or question in Parkinson’s research.
• ·     Designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields.
• ·     Must address at least one of the FY22 PRP Focus Areas.
• ·     Preliminary data to support feasibility is encouraged but not required.
• ·     Submission of a Letter of Intent is required prior to full application submission. 
• ·     Clinical trials are allowed.
• ·    Level 1: Maximum funding of $3.0M in total costs
• ·    Level 2: Maximum funding of $9.0M in total costs
• ·    The maximum period of performance is 4 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca.

This Ship Time program is aimed at all NSERC-funded researchers who intend to use a vessel for their DG-supported research in the coming years. It applies to the following: Department of Fisheries and Oceans (DFO)/ Canadian Coast Guard (CCG) vessels, undersea vehicles operated by the  Canadian Scientific Submersible Facility or other similar research platforms, and any other vessels crewed in conformance with the  Canada Shipping Act, 2001 (or similar, for foreign vessels).

Ship Time grants support ongoing DG research programs. These grants recognize the high costs associated with chartering research vessels in Canada and abroad. Applicants must hold a Discovery Grant (or be successful in the current DG competition) to be eligible to receive a Ship Time grant. Recipients of Ship Time grants must use the funds as described in the application. Requests to use an alternate vessel will be assessed on a case-by-case basis.

Ship Time applicants may apply for more than one vessel at a time. Should the two vessels be part of the same project (e.g., a remotely operated vehicle and a support vessel), only one application is to be submitted.

The normal duration of Ship Time grants is one year. Two-year grants will be considered in exceptional circumstances, where the project completion requires a firm commitment of funding for more than one year